CLINICAL RESEARCH: CLINICAL TRIAL
Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)
Mauro Maioli, MD*,
Francesco Bellandi, MD,
Mario Leoncini, MD,
Anna Toso, MD and
Roberto Piero Dabizzi, MD
Division of Cardiology, Misericordia e Dolce Hospital, Prato, Italy
Manuscript received July 27, 2006;
revised manuscript received December 6, 2006,
accepted December 10, 2006.
* Reprint requests and correspondence: Dr. Mauro Maioli, Via degli Arcipressi 3, 50143, Florence, Italy. (Email: mauromaioli{at}tiscali.it).
Objectives: This prospective randomized trial evaluates the impact of early abciximab administration on angiographic and left ventricular function parameters.
Background: Glycoprotein IIb/IIIa inhibitors improve myocardial reperfusion in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI), but optimal timing of administration remains unclear.
Methods: Two-hundred ten consecutive patients with first AMI undergoing primary PCI were randomized to abciximab administration either in the emergency room (early group: 105 patients) or in the catheterization laboratory, after coronary angiography (late group: 105 patients). Primary end points were initial Thrombolysis In Myocardial Infarction (TIMI) flow grade, corrected TIMI frame count (cTFC), and myocardial blush grade (MBG), as well as left ventricular function recovery as assessed by serial echocardiographic evaluations.
Results: Angiographic pre-PCI analysis showed a significantly better initial TIMI flow grade 3 (24% vs. 10%; p = 0.01), cTFC (78 ± 30 frames vs. 92 ± 21 frames; p = 0.001), and MBG 2 or 3 (15% vs. 6%; p = 0.02) favoring the early group. Consistently, post-PCI tissue perfusion parameters were significantly improved in the early group, as assessed by 60-min ST-segment reduction  70% (50% vs. 35%; p = 0.03) and MBG 2 or 3 (79% vs. 58%; p = 0.001). Left ventricular function recovery at 1 month was significantly greater in the early group (mean gain ejection fraction 8 ± 7% vs. 6 ± 7%, p = 0.02; mean gain wall motion score index 0.4 ± 0.3 vs. 0.3 ± 0.3, p = 0.03).
Conclusions: In patients with AMI treated with primary PCI, early abciximab administration improves pre-PCI angiographic findings, post-PCI tissue perfusion, and 1-month left ventricular function recovery, possibly by starting early recanalization of the infarct-related artery.
|
Abbreviations and Acronyms
| | AMI = acute myocardial infarction | | cTFC = corrected Thrombolysis In Myocardial Infarction frame count | | EF = ejection fraction | | IRA = infarct-related artery | | LV = left ventricle/ventricular | | MACE = major adverse cardiac events | | MBG = myocardial blush grade | | PCI = percutaneous coronary intervention | | STEMI = ST-segment elevation myocardial infarction | | TIMI = Thrombolysis In Myocardial Infarction | | WMSI = wall motion score index |
|
This article has been cited by other articles:
|
|
|
|
 
G De Luca, C M Gibson, F Bellandi, S Murphy, M Maioli, M Noc, U Zeymer, D Dudek, H-R Arntz, S Zorman, et al.
Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis
Heart,
December 1, 2008;
94(12):
1548 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca
Adjunctive antithrombotic therapy during primary percutaneous coronary intervention
Eur. Heart J. Suppl.,
December 1, 2008;
10(suppl_J):
J2 - J14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ortolani, A. Marzocchi, C. Marrozzini, T. Palmerini, F. Saia, N. Taglieri, F. Baldazzi, G. Dall'Ara, P. Nardini, S. Gianstefani, et al.
Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network
Eur. Heart J.,
November 7, 2008;
(2008)
ehn480v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, D. Kivelitz, et al.
Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial
Circulation,
July 1, 2008;
118(1):
49 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis, M. Tendera, M. A. de Belder, A. J. van Boven, P. Widimsky, L. Janssens, H.R. Andersen, A. Betriu, S. Savonitto, J. Adamus, et al.
Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
N. Engl. J. Med.,
May 22, 2008;
358(21):
2205 - 2217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Moliterno and K. M. Ziada
The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
J. Am. Coll. Cardiol.,
February 5, 2008;
51(5):
536 - 537.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Early Abciximab Improves Peri- and Postprocedural Outcomes of Primary PCI
Journal Watch Cardiology,
May 9, 2007;
2007(509):
3 - 3.
[Full Text]
|
|
|
|
